Anti-EphA4 antibody
AssigneeEisai R&D Management Co., Ltd.
InventorsEiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani
Life of this patent
Estimating the term…
Abstract
Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
Claims15
An anti-EphA4 antibody, wherein
- the anti-EphA4 antibody comprises heavy and light chains, and comprises:
- (a) a heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 44;
- (b) a heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 27;
- (c) a heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 28;
- (d) a light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 29;
- (e) a light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 30;
- and
- (f) a light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 31.
An anti-EphA4 antibody, wherein the anti-EphA4 antibody comprises heavy and light chains, the heavy chain comprises the amino acid sequence shown in SEQ ID NO. 59, and the light chain comprises the amino acid sequence shown in SEQ ID NO. 60.
An anti-EphA4 antibody, wherein the anti-EphA4 antibody comprises heavy and light chains, the heavy chain comprises the amino acid sequence shown in SEQ ID NO. 59, the light chain comprises the amino acid sequence shown in SEQ ID NO. 60, and the C-terminal lysine of the heavy chain is deleted.
Dependencies are inferred from the claim text.